Takeda Haruna et al. used genetically defined benign tumor-derived organoids carrying two frequent gene mutations (APC and KRAS mutations; AK organoids), which mainly contribute to the disease progress in the early stage of colorectal cancer (CRC) [82]. The gene discussed is APC; the disease is neoplasm.